Share Email Print

Proceedings Paper

Photodynamic therapy in patients with recurrent gynecological carcinomas
Author(s): Heinz Hetzel; Elisabeth Mueller; Herwig Kostron
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Patients with recurrent gynecological carcinomas have a poor prognosis with a median survival time of 3 - 6 months. Four patients with recurrent vulva carcinomas, one patient with a recurrent breast cancer, and one with a recurrent cervical carcinoma underwent PDT after parenteral or topical sensitization with Photosan 3. Of those patients two women made a complete recovery with no evidence of disease 27 and 24 months after. One patient responded partially with two recurrences which were retreated twice after topical sensitization, she has survived 16 months. The remaining patients showed partial response and died 3 and 8 months after PDT. The energy delivered by an argon-dye-laser ranged between 225 and 750 J/cm2. Photosan 3 was given intravenously at a dose of 2.5 mg/kg body weight and was tolerated without any allergic reaction. A response rate of nearly 50% in recurrent gynecological malignancies encourages us to pursue PDT in gynecological diseases.

Paper Details

Date Published: 5 March 1993
PDF: 4 pages
Proc. SPIE 1616, International Conference on Photodynamic Therapy and Laser Medicine, (5 March 1993); doi: 10.1117/12.136945
Show Author Affiliations
Heinz Hetzel, Univ. of Innsbruck (Austria)
Elisabeth Mueller, Univ. of Innsbruck (Austria)
Herwig Kostron, Univ. of Innsbruck (Austria)

Published in SPIE Proceedings Vol. 1616:
International Conference on Photodynamic Therapy and Laser Medicine

© SPIE. Terms of Use
Back to Top